Antimicrobial resistance in Clostridium difficile

International Journal of Antimicrobial Agents

Volumn 34, Issue 6, 2009, Pages 516-522

  Huang, Haihui ^a,b   Weintraub, Andrej ^b   Fang, Hong ^b   Nord, Carl Erik ^b  

^a FUDAN UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antimicrobial susceptibility; Clostridium difficile; Resistance mechanisms

Indexed keywords

ANTIINFECTIVE AGENT; BACITRACIN; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; FIDAXOMICIN; FUSIDIC ACID; GATIFLOXACIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN; RIFAXIMIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG RESPONSE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS;

EID: 70350377796     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.09.012     Document Type: Short Survey

References (70)

1. Hall I.C., and O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 49 (1935) 390-402
2. Bartlett J.G., Chang T.W., and Gurwith M. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298 (1978) 531-534
3. O'Connor J.R., Johnson S., and Gerding D.N. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136 (2009) 1913-1924
4. Goorhuis A., Bakker D., Corver J., Debast S.B., Harmanus C., Notermans D.W., et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47 (2008) 1162-1170
5. Rouphael N.G., O'Donnell J.A., Bhatnagar J., Lewis F., Polgreen P.M., Beekmann S., et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol 198 (2008) 635.e1-635.e6
6. Owens Jr. R.C., Donskey C.J., Gaynes R.P., Loo V.G., and Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46 Suppl. 1 (2008) S19-31
7. Muto C.A., Pokrywka M., Shutt K., Mendelsohn A.B., Nouri K., Posey K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26 (2005) 273-280
8. Kelly C.P., and LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 359 (2008) 1932-1940
9. Leroi M.J., Siarakas S., and Gottlieb T. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid. Eur J Clin Microbiol Infect Dis 21 (2002) 72-74
10. B) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 51 (2003) 599-603
11. Drummond L.J., McCoubrey J., Smith D.G., Starr J.M., and Poxton I.R. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 52 (2003) 259-263
12. Bourgault A.M., Lamothe F., Loo V.G., Poirier L., and CDAD-CSI Study Group. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. Antimicrob Agents Chemother 50 (2006) 3473-3475
13. Aspevall O., Lundberg A., Burman L.G., Akerlund T., and Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 50 (2006) 1890-1892
14. Schmidt C., Löffler B., and Ackermann G. Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagn Microbiol Infect Dis 59 (2007) 1-5
15. Mutlu E., Wroe A.J., Sanchez-Hurtado K., Brazier J.S., and Poxton I.R. Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol 56 (2007) 921-929
16. Hecht D.W., Galang M.A., Sambol S.P., Osmolski J.R., Johnson S., and Gerding D.N. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 51 (2007) 2716-2719
17. Brazier J.S., Raybould R., Patel B., Duckworth G., Pearson A., Charlett A., et al. Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English hospitals, 2007-08. Euro Surveill (2008) 13 pii:19000
18. Martin H., Willey B., Low D.E., Staempfli H.R., McGeer A., Boerlin P., et al. Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol 46 (2008) 2999-3004
19. Huang H., Wu S., Wang M., Zhang Y., Fang H., Palmgren A.C., et al. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Int J Antimicrob Agents 33 (2009) 339-342
20. Terhes G, Urban E, Soki J, Szikra L, Konkoly-Thege M, Vollain M, et al. Assessment of changes in the epidemiology of Clostridium difficile isolated from diarrheal patients in Hungary. Anaerobe 2009, February 8 [Epub ahead of print].
21. Huang H, Fang H, Weintraub A, Nord CE. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect 2009, July 15 [Epub ahead of print].
22. Barbut F., Mastrantonio P., Delmée M., Brazier J., Kuijper E., Poxton I., and European Study Group on Clostridium difficile (ESGCD). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13 (2007) 1048-1057
23. B) type resistance. J Med Microbiol 55 (2006) 207-213
24. John R., and Brazier J.S. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 61 (2005) 11-14
25. Labbé A.C., Poirier L., Maccannell D., Louie T., Savoie M., Béliveau C., et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52 (2008) 3180-3187
26. Brazier J.S., Fawley W., Freeman J., and Wilcox M.H. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 48 (2001) 741-742
27. Peláez T, Sanchez R, Blazquez R, Catalan P, Munoz P, Bouza E. Metronidazole resistance in Clostridium difficile: a new emerging problem? In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 4-7 October 1994, Orlando, FL. Abstract E-34:50.
28. Peláez T., Alcalá L., Alonso R., Rodríguez-Créixems M., García-Lechuz J.M., and Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46 (2002) 1647-1650
29. Peláez T., Cercenado E., Alcalá L., Marín M., Martín-López A., and Martínez-Alarcón J. Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 46 (2008) 3028-3032
30. Baines S.D., O'Connor R., Freeman J., Fawley W.N., Harmanus C., Mastrantonio P., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62 (2008) 1046-1052
31. Gal M., and Brazier J.S. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J Antimicrob Chemother 54 (2004) 109-116
32. Leiros H.K., Kozielski-Stuhrmann S., Kapp U., Terradot L., Leonard G.A., and McSweeney S.M. Structural basis of 5-nitroimidazole antibiotic resistance: the crystal structure of NimA from Deinococcus radiodurans. J Biol Chem 279 (2004) 55840-55849
33. Lubbe M.M., Stanley K., and Chalkley L.J. Prevalence of nim genes in anaerobic/facultative anaerobic bacteria isolated in South Africa. FEMS Microbiol Lett 172 (1999) 79
34. Dworczynski A., Sokó B., and Meisel F. Antibiotic resistance of Clostridium difficile isolates. Cytobios 65 (1991) 149-153
35. Woodford N. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist 7 (2001) 229-236
36. Spigaglia P., and Mastrantonio P. Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol 53 (2004) 1129-1136
37. Kuijper E.J., Barbut F., Brazier J.S., Kleinkauf N., Eckmanns T., Lambert M.L., et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill (2008) 13 pii:18942
38. Bacci S., St-Martin G., Olesen B., Bruun B., Olsen K.E., Nielsen E.M., et al. Outbreak of Clostridium difficile 027 in North Zealand, Denmark, 2008-2009. Euro Surveill (2009) 14 pii:19183
39. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 34 (2002) 482-492
40. Roberts M.C., Sutcliffe J., Courvalin P., Jensen L.B., Rood J., and Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 43 (1999) 2823-2830
41. Wüst J., and Hardegger U. Transferable resistance to clindamycin, erythromycin, and tetracycline in Clostridium difficile. Antimicrob Agents Chemother 2 (1983) 784-786
42. Farrow K.A., Lyras D., and Rodd J.I. Genomic analysis of the erythromycin resistance element Tn5398 from Clostridium difficile. Microbiology 147 (2001) 2717-2728
43. Rice L.B. Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants. Antimicrob Agents Chemother 42 (1998) 1871-1877
44. Villedieu A., Roberts A.P., Allan E., Hussain H., McNab R., Spratt D.A., et al. Determination of the genetic support for tet(W) in oral bacteria. Antimicrob Agents Chemother 51 (2007) 2195-2197
45. Mullany P., Wilks M., Lamb I., Clayton C., Wren B., and Tabaqchali S. Genetic analysis of a tetracycline resistance element from Clostridium difficile and its conjugal transfer to and from Bacillus subtilis. J Gen Microbiol 136 (1990) 1343-1349
46. Spigaglia P., Barbanti F., and Mastrantonio P. New variants of the tet(M) gene in Clostridium difficile clinical isolates harbouring Tn916-like elements. J Antimicrob Chemother 57 (2006) 1205-1209
47. Spigaglia P., Barbanti F., and Mastrantonio P. Tetracycline resistance gene tet(W) in the pathogenic bacterium Clostridium difficile. Antimicrob Agents Chemother 52 (2008) 770-773
48. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J.S., Barbut F., Delmée M., et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57 (2008) 784-789
49. Oh H., and Edlund C. Mechanism of quinolone resistance in anaerobic bacteria. Clin Microbiol Infect 9 (2003) 512-517
50. Ackermann G., Tang Y.J., Kueper R., Heisig P., Rodloff A.C., Silva Jr. J., et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 45 (2001) 2348-2353
51. Drudy D., Quinn T., O'Mahony R., Kyne L., O'Gaora P., and Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58 (2006) 1264-1267
52. Spigaglia P., Barbanti F., Louie T., Barbut F., and Mastrantonio P. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. Antimicrob Agents Chemother 53 (2009) 2463-2468
53. Curry S.R., Marsh J.W., Shutt K.A., Muto C.A., O'Leary M.M., Saul M.I., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 48 (2009) 425-429
54. O'Connor J.R., Galang M.A., Sambol S.P., Hecht D.W., Vedantam G., Gerding D.N., et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 52 (2008) 2813-2817
55. Norén T., Akerlund T., Wullt M., Burman L.G., and Unemo M. Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile. Antimicrob Agents Chemother 51 (2007) 1840-1843
56. Farrow K.A., Lyras D., and Rodd J.I. The macrolide-lincosamide-streptogramin B resistance determinant from Clostridium difficile 630 contains two erm(B) genes. Antimicrob Agents Chemother 44 (2000) 411-413
57. B) resistance determinants in strains of Clostridium difficile. Microb Drug Resist 8 (2002) 45-53
58. Vedantam G., and Hecht D.W. Antibiotics and anaerobes of gut origin. Curr Opin Microbiol 6 (2003) 457-461
59. Pépin J., Saheb N., Coulombe M.A., Alary M.E., Corriveau M.P., Authier S., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 (2005) 1254-1260
60. Dridi L., Tankovic J., Burghoffer B., Barbut F., and Petit J.C. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 46 (2002) 3418-3421
61. Garey K.W., Salazar M., Shah D., Rodrigue R., and DuPont H.L. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 42 (2008) 827-835
62. Jiang ZD, Dupont HL, La Rocco M, Garey KW. In vitro activity of rifaximin and rifampin against clinical isolates of Clostridium difficile in Houston, Texas. Anaerobe 2009, February 15 [Epub ahead of print].
63. Campbell E.A., Korzheva N., Mustaev A., Murakami K., Nair S., Goldfarb A., et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104 (2001) 901-912
64. Bartlett J.G. New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep 11 (2009) 21-28
65. Norén T., Wullt M., Akerlund T., Bäck E., Odenholt I., and Burman L.G. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 50 (2006) 3028-3032
66. Wong S.S., Woo P.C., Luk W.K., and Yuen K.Y. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 34 (1999) 1-6
67. Poilane I., Cruaud P., Torlotin J.C., and Collignon A. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin Microbiol Infect 6 (2000) 155-156
68. Bolton R.P., and Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27 (1986) 1169-1172
69. Huang H., and Nord C.E. Can metronidazole still be used for treatment of Clostridium difficile infections?. Curr Infect Dis Rep 11 (2009) 3-6
70. MacGowan AP. Breakpoint evolution or the need for continuous revision. In: Official Symposium Session of the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland. Symposium S420.